Congressman Pushes DOJ for Cannabis Rescheduling Timeline Update
Federal lawmaker demands transparency on DEA's Schedule III review process as industry awaits regulatory clarity that could unlock institutional investment.
A congressional representative has formally requested an update from the Department of Justice regarding the timeline for cannabis rescheduling, intensifying pressure on federal agencies to provide clarity on the regulatory review process. The inquiry comes as the cannabis industry continues waiting for the DEA's final decision on moving marijuana from Schedule I to Schedule III under the Controlled Substances Act.
The rescheduling process has created uncertainty across cannabis markets, with publicly traded operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) trading at depressed valuations despite strong operational performance. Moving cannabis to Schedule III would eliminate the 280E tax burden that currently prevents cannabis companies from deducting standard business expenses, potentially improving margins by 15-25% across the sector.
Institutional investors remain largely sidelined due to federal prohibition, limiting access to traditional banking and capital markets. A Schedule III designation would not fully resolve these issues but represents the most significant federal policy shift since state-level legalization began. The regulatory limbo has contributed to a challenging capital environment, with many MSOs trading below book value despite generating positive cash flows.
Concurrent developments include bipartisan Senate movement on psychedelics legislation and ongoing state-level cannabis policy debates in Mississippi and Indiana. These parallel tracks demonstrate growing political momentum for drug policy reform, though federal cannabis rescheduling remains the primary catalyst investors are monitoring for sector-wide revaluation.
The congressional pressure on DOJ reflects broader frustration with the pace of federal cannabis policy evolution. While the Biden administration initiated the rescheduling review in 2022, the extended timeline has created operational challenges for cannabis companies navigating conflicting state and federal frameworks. Any concrete timeline from DOJ would provide much-needed visibility for strategic planning and capital allocation decisions across the industry.